Table 6

Patients' WR-1065 and mesna peak levels immediately after the first amifostine and the first mesna infusions, respectively

	WR-1065		Mesna
	WR-SH	Total Reducible WR-1065	M-SH	Total Reducible Mesna
	μM
Patient 1
Plasma	80	94	277	523
RBC	100	103	95	140
Patient 2
Plasma	67	59	244	317
RBC	80	111	45	31
Patient 5
Plasma			520	792
RBC			80	85
Patient 6
Plasma			9	93
RBC			6

Patients 1 and 2 received amifostine (825 mg/m² i.v. over 15 min) followed by mesna (400 mg/m² i.v. over 15 min). Patient 5 and 6 received only mesna (750 mg/m² i.v. push and 360 mg/m² i.v. over 30 min, respectively). The concentrations of the free thiols (i.e., WR-SH and M-SH) were set equal to the amounts of the bimane derivatives in plasma and blood cell acid supernatants in the absence of DTT, as described under Materials and Methods(sample analysis, reaction 2). Final concentrations were calculated using the measured volume of plasma and blood cells. The concentrations of the total reducible thiols (i.e., free thiols plus LMW-disulfides) were set equal to the amounts of the bimane derivatives in plasma and blood cell acid supernatants in the presence of DTT, as described underMaterials and Methods (sample analysis, reaction 1). Values for the LMW disulfides were calculated as thiol equivalents (e.g., one equivalent of dimesna equals two equivalents of M-SS-LMW).